Boyan Litchev
Keine laufenden Positionen mehr
Vermögen: 2 576 $ am 31.03.2024
Profil
Boyan Litchev formerly worked at Akcea Therapeutics, Inc., as Medical Director, Halozyme Therapeutics, Inc., as Head-Clinical Development Oncology, Poseida Therapeutics, Inc., as Head-Clinical Development Solid Tumors, Shoreline Biosciences, Inc., as Senior VP & Head-Clinical Development Oncology, and Indaptus Therapeutics, Inc., as Chief Medical Officer.
Dr. Litchev received his doctorate degree from Medical University of Plovdiv.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2023 | 1 150 ( 0,01% ) | 2 576 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Boyan Litchev
| Unternehmen | Position | Ende |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Shoreline Biosciences, Inc.
 Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Corporate Officer/Principal | - |
| POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| INDAPTUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Boyan Litchev
| Medical University of Plovdiv | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| INDAPTUS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Shoreline Biosciences, Inc.
Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Health Technology |
